(Reuters) – Pfizer Inc/BioNTech SE’s and Moderna’s updated bivalent COVID-19 vaccines helped prevent symptomatic infections from the XBB-related subvariants of Omicron, according to an analysis from the U.S. Centers for Disease Control and Prevention (CDC) released on Wednesday.